GW Pharmaceuticals Plc’s pioneering cannabis-based medicine has been launched in Canada, the British firm said on Monday.

GW said its Sativex medicine was now available by prescription in Canada to treat pain in adults with multiple sclerosis.

GW’s shares plunged earlier this month when the firm lost an appeal with UK regulators, meaning it will have to produce more data on Sativex before it is considered for approval in Britain.